This site is intended for healthcare professionals

NMPA regulatory agency for China granted conditional approval for toripalimab to treat recurrent or metastatic nasopharyngeal carcinoma.- Shanghai Junishi Biosciences

Read time: 1 mins
Last updated:23rd Feb 2021
Published:23rd Feb 2021
Condition: Nasopharyngeal Carcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest